Home Antibody All anti-FOXL2 antibodies
Also for FOXL2 (NM_023067)
| Peptide with sequence C-DSKTGALHSRLDL, from the C Terminus of the protein sequence according to NP_075555.|
|Test: Human, Mouse. Expected from seq similarity: Human, Mouse, Rat, Cow
||ELISA: 1:32,000. WB: 0.5-1.5ug/ml.
|Supplied at 0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin.|
| Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide. Supplied at 0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin. Aliquot and store at -20°C. Minimize freezing and thawing.
|Homo sapiens forkhead box L2 (FOXL2)|
|BPES; BPES1; PFRK; PINTO; POF3|
Entrez Gene 668 Human
Entrez Gene 26927 Mouse
Entrez Gene 367152 Rat
|Defects in FOXL2 are a cause of blepharophimosis, ptosis, and epicanthus inversus syndrome (BPES) [MIM:110100]; also known as blepharophimosis syndrome. It is an autosomal dominant disorder characterized by eyelid dysplasia, small palpebral fissures, drooping eyelids and a skin fold running inward and upward from the lower lid. In type I BPSE (BPES1) eyelid abnormalities are associated with female infertility. Affected females show an ovarian deficit due to primary amenorrhea or to premature ovarian failure (POF). In type II BPSE (BPES2) affected individuals show only the eyelid defects. There is a mutational hotspot in the region coding for the poly-Ala domain, since 30% of all mutations in the ORF lead to poly-Ala expansions, resulting mainly in BPES type II.|
|Transcription FactorsDruggable Genome |
* Availability is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
TA302879 (0.5ug/ml) staining of Human Ovary lysate (35ug protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence.
TA302879 (2ug/ml) staining of paraffin embedded Human Ovary. Steamed antigen retrieval with citrate buffer pH 6, AP-staining.